Engineered Immune Cells
PreclinicalBiologic
Engineered Immune Cells is one of 6 biologic programs targeting Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Cancer
#DrugCompanyPhaseTrials
1Zofran
NovartisPhase 1
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
Decadron
AAspen Global Incorporated
Phase 1
Zyprexa
MMODAG GmbH
Phase 1
Netupitant/palonosetron Hydrochloride
UUniversity of Rochester NCORP Research Base
Phase 1
Engineered Immune Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Engineered Immune Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details